Pfizer Inc. (PFE)
Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on Friday following data from a late-stage study.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% change compared to its last close.
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
The latest dividend declarations, combined with stock price movements, have pushed PFE's yield to be almost twice as JNJ's. But I want to caution you to look beyond yield (and P/E too) and examine other aspects, especially those often overlooked by dividend investors. JNJ offers better growth, a stronger track record, and also a safer payout.
Is Pfizer Stock Undervalued at Current Prices?
Pfizer (PFE -0.07%) stock investors are curious about the valuation and prospects for the healthcare company.
Should You Buy Pfizer Stock Right Now in 2025?
Pfizer (PFE 0.20%) is an interesting healthcare company with excellent prospects for cash flow growth.
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer's PFE stock has risen 5.6% in the past month. This was due to the company's encouraging guidance for 2025 issued in mid-December 2025.
The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP
Berkshire Hathaway, The Home Depot, Pfizer and AMREP are included in this Analyst Blog.
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
In the latest trading session, Pfizer (PFE) closed at $26.61, marking a +0.3% move from the previous day.
Here's Why Pfizer (PFE) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pfizer's 2025 Comeback: What's Driving Growth
Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 billion through balance sheet optimization. Investing $10.7-$11.7 billion in R&D, focusing on obesity treatments, oncology, and vaccines to address unmet needs.
Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact
The small-cap won't receive an expected payout in the first quarter, creating a cash overhang.
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.
